Following rusfertide’s triumphant Phase III trial last year, Protagonist must decide how involved to be in future development ...

NEWARK, CA / ACCESS Newswire / January 7, 2026 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today ...

Takeda and Protagonist Therapeutics have jointly submitted a NDA seeking approval from the US FDA for rusfertide to treat ...

Josh Cotts is a Senior Contributor at Game Rant. He graduated Summa Cum Laude from Arizona State University in 2019 with a B.A. in Mass Communications & Media Studies and has been commended since ...

Johnson & Johnson’s latest prospective offering to the IL-23 psoriasis space—a Protagonist Therapeutics-partnered once-daily oral peptide—has passed a phase 3 checkpoint with results that could pad ...

Protagonist Therapeutics' stock has experienced significant volatility over the past three years, with multiple setbacks and recoveries. The company's lead drug candidate, Rusfertide, indicated for ...

Protagonist Therapeutics (PTGX) is gearing up to report top-line results from its phase 3 VERIFY study using its subcutaneous injectable Hepcidin Mimetic rusfertide [PTG-300] for the treatment of ...